Data from a drug-drug interaction study involving VECTIBIX and irinotecan in patients with mCRC indicate that the pharmacokinetics of irinotecan and its active metabolite, SN-38, are not altered when the drugs are co-administered.
Results from a cross-study comparison indicated that irinotecan-containing regimens (IFL or FOLFIRI) have no effect on the pharmacokinetics of panitumumab.